Biomedical subjects

Bo Yao

Publications and source records attributed to Bo Yao.

24 records · Page 2Linked to original sources

PubMed2004

Differential expression of thyroid-stimulating hormone beta subunit in gonads during sex reversal of orange-spotted and red-spotted groupers.

We have cloned and characterized the full-length cDNA encoding thyroid-stimulating hormone beta-subunit (TSHbeta) from orange-spotted grouper Epinephelus coioides. It contains 913 nucleotides with an open reading frame encoding 146 amino acids with a 20 amino acid signal peptide. The grouper mature TSHbeta has 75, 70, 61, 59, 41, 42 and 40% identities to that of rainbow trout, Atlantic salmon, zebrafish, European eel, chicken, mouse and human, respectively. RT-PCR analysis indicated that the TSHbeta mRNA was expressed abundantly not only in pituitary but also in gonads. A more interesting finding is to reveal the differential TSHbeta expressions between the ovaries and the transitional gonads or testes in natural individuals of orange-spotted grouper and red-spotted grouper Epinephelus akaara, and in artificial sex reversal individuals of red-spotted grouper induced by MT feeding. In situ hybridization localization provided direct evidence that the TSHbeta was transcribed in the germ cells. In the growing oocytes, the TSHbeta transcripts were concentrated on the ooplasm periphery. In testicular tissues, the intensively expressed TSHbeta cells were found to be spermatogonia and spermatocytes in the spermatogenic cysts. This is the first report of a TSHbeta expressed in the gonads of any vertebrates in addition to the expected expression in the pituitary, and it expresses more transcripts in the gonads during sex reversal or testis than in the ovaries both in E. coioides and E. akaara. Importantly, the TSHbeta identification in germ cells allows us to further investigate the functional roles and the molecular mechanisms in gametogenesis of groupers, especially in sex reversal and in spermatogenesis.

Amino Acid Sequence↗

PubMed2004

Genotype and allele frequency of the variable number tandem repeat polymorphism in the VNTR6-1st of the of human telomerase reverse transcriptase (hTERT) gene in Chinese population.

The variable number of tandem repeat (VNTR) polymorphism in the intron 6 of the human telomerase reverse transcriptase(hTERT) was investigated. Seven alleles of 18, 20, 21, 22, 23, 26 and 35 repeats of the 36 bp VNTR6-1st and 14 genotypes were identified among 210 unrelated healthy Chinese individuals (Han people) living in Beijing. The 20, 22 and 35 repeats were the most frequent alleles which accounted for 94.76% of the total alleles observed. The allele frequency of the Chinese population showed no difference with that of the Korea population living in Pusan except for allele of 35 repeats. But the 5' flanking region of VNTR6-1st polymorphic sequence of the Chinese population included a 53-bp insert compared with that of korea population except for some alleles of 22 repeats.

Alleles↗

PubMed2003

[Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation].

OBJECTIVE: To study the clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic hematopoietic stem cell transplantation (NAST) in treatment of hematological diseases. METHODS: Nonmyeloablative pretreatment was given to 42 patients with hematological diseases, 26 males and 16 females with the median age of 37, that were matched with the donors in terms of HLA, such as CD3 monoclonal antibody, cyclosporine A, cyclophosphamide (CTX) and cytarabine for patients with leukemia among which 6 were given fludarabine in addition, and CTX and antilymphocyte globulin for patients with myeloproliferative disease and aplastic anemia, thus practicing nonmyeloablative allogeneic stem cell transplantation (NAST). The incidence of graft-versus-host disease (GVHD) and survival were observed. RESULTS: Donor-recipient hematopoietic cell chimerism was formed in 42 patients, with 18 cases of full donor chimerism (FDC) and 24 cases of mixed chimerism (MC). Of the 42 patients, 10 (23.8%) developed acute GVHD (aGVHD). The incidence of aGVHD in group MC (2/24, 8.9%) was significantly lower than that in group FDC (8/24, 44.4%, P < 0.05). In addition, eight (19.1%) developed chronic GVHD (cGVHD). The incidence of cGVHD was also lower in group MC (4/24, 16.7%) in comparison with 4/18 (23.2%) in group FDC (P > 0.05). There was no difference in recovery time of neutrophils and platelets (P > 0.05) between the two groups. Thirty-one patients still survived and there was no significant difference between the group FDC and MC in terms of survival rate and leukemia relapse rate. CONCLUSION: Compared with full donor chimerism, mixed chimerism significantly alleviates the incidence of aGVHD and does not delay the hematopoietic reconstitution. It may be an ideal model of engraftment that mixed chimerism converts to full donor chimerism within several months after NAST.

Adolescent↗

PubMed2003

[The clinical research of nonmyeloablative allogeneic peripheral blood hematopoietic stem cells transplantation for hematological diseases].

OBJECTIVE: To explore the significance of nonmyeloablative allogeneic peripheral blood hematopoietic stem cell transplantation in the treatment of hematological diseases. METHODS: A nonmyeloablative conditioning regimen consisted of CD(3) monoclonal antibody, cyclosporine A, cyclophosphamide and cytarabine was used for allogeneic stem cell transplantation in 33 patients with hematological diseases. Of them, 11 were acute leukemia (AL) in first complete remission (CR(1)), 4 AL-CR(2) approximately 3, 3 refractory AL, 4 severe aplastic anemia (SAA), 7 chronic myeloid leukemia (CML), 2 myelodysplastic syndrome, 1 each of chronic lymphocytic leukemia (CLL) and myelofibrosis. RESULTS: All 33 patients passed the hematopoietic suppression stage smoothly and achieved engraftment of the donor cells. There were 24 cases of full donor chimerism (13 cases converted from mixed chimerism), 4 mixed chimerism (MC) and 5 developed graft rejection. Of the 33 cases, 7 (21.2%) developed acute GVHD and chronic GVHD, 25 (75.8%) still live and 8 (24.2%) died. CONCLUSIONS: Nonmyeloablative allogeneic peripheral blood stem cells transplantation is a safe, less toxic and curative approach for patients with hematological disease.

Acute Disease↗

PubMed2003

[Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].

OBJECTIVE: To investigate the therapeutic effect of conditioning regimen containing fludarabine in nonmyeloablative allogeneic peripheral blood stem cells transplantation (NAST) in the treatment of hematological diseases. METHODS: Thirty-six patients with acute leukaemia, severe aplastic anaemia, MDS and myelofibrosis received NAST from HLA matched donors' G-CSF mobilized peripheral blood stem cells after nonmyeloabalative conditioning. The conditioning regimen consisted of CTX, Ara-C, CsA, anti-CD(3) antibody or anti-thymocyte globulin and with or without fludarabine. GVHD prophylaxis was performed with cyclosporine combined methotrexate (no MMF group, n = 5) or mycophenolate mofetil (MMF group, n = 31). RESULTS: All of the treatment was generally well tolerated and all cases achieved engrafted of the donor cells. In fludarabine group, engraftment was observed in 87.5% (14/16) patients with complete donor chimerism, graft failure was 12.5% (2/16) and in no fludarabine group, 80% (16/20) and 20% (4/20), respectively. The incidence of acute GVHD (grade I - IV) was 27.8% (10/36) and chronic GVHD 22.2% (8/36). In fludarabine group, grade I - II aGVHD was 37.5%, in no fludarabine group, 20%. cGVHD was 12.5% in fludarabine group and in no fludarabine group 30%, respectively. Interstitial pneumonia (IP) was observed in 16.7% (6/36) of the patients, being 18.7% (3/16) and 15% (3/20) in fludarabine and no fludarabine group, respectively. Overall survival rate was 80.5% (29/36) with a median follow-up of 13 months. CONCLUSIONS: There was no significant difference between fludarabine based (n = 16) and non-fludarabine based conditioning regimen (n = 20) in NAST for the treatment of hematological diseases, regarding for incidence of GVHD, IP, engraftment and survival.

Adolescent↗

PubMed2001

[Nonmyeloablative Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for Therapy of Hematologic Diseases]

The objectve of this investigation was to explore the use of nonmyeloablative allogeneic peripheral blood stem cell tranplantation for treatment of hematologic diseases. Six patients were included: 3 cases with acute leukemia in first complete remission (2 AML and 1 ALL), 2 severe aplastic anemias and 1 chronic myeloid leukemia in chronic phase. All of the 6 cases were received HLA-identical siblings donor peripheral blood stem cell transplantation after a nonmyeloablative conditioning. The donor cells were engrafted in all patients (3 cases were full engrafment of donor cells and 3 were mixed chimerism). Hematopoietic recovery was appeared in all of the cases (ANC recovered to more than 0.5 x 10(9)/L and platelet count to more than 30 x 10(9)/L on day 9 to day 21 and day 14 to day 28 after transplantation, respectively). Two patients developed III or IV degree GVHD. Our preliminary results suggest that the procedure is more safe, efficient and less complications than myeloablative conditioning regimens and represents another new approach in the management of patients with hematologic diseases.

Journal Article↗